|
Orthologous residues
|
|
IL9R (human): Y407‑p, IL9R (mouse): Y405‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Disease tissue studied:
lymphoma, T cell lymphoma
|
|
Relevant cell lines - cell types - tissues:
BaF3 ('B lymphocyte, precursor'), BW5147 (T lymphocyte)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
IL-9
|
|
|
|
increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
apoptosis, inhibited, cell growth, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
DNA
|
|
Induces
|
molecular association, regulation
|
|
EMSA
|
|
|
Comments:
required for IL9-induced binding to GRR oligonucleotide complex containing activated STAT1-alpha, STAT3 and STAT5.
|
